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SHORT REPORT
Common colorectal cancer risk alleles contribute to
the multiple colorectal adenoma phenotype, but do
not influence colonic polyposis in FAP
Timothy HT Cheng1, Maggie Gorman1, Lynn Martin1, Ella Barclay1, Graham Casey2, Colon Cancer Family
Registry7, CGEMS8, Brian Saunders3, Huw Thomas4, Sue Clark5 and Ian Tomlinson*,1,6
The presence of multiple (5–100) colorectal adenomas suggests an inherited predisposition, but the genetic aetiology of this
phenotype is undetermined if patients test negative for Mendelian polyposis syndromes such as familial adenomatous polyposis
(FAP) and MUTYH-associated polyposis (MAP). We investigated whether 18 common colorectal cancer (CRC) predisposition
single-nucleotide polymorphisms (SNPs) could help to explain some cases with multiple adenomas who phenocopied FAP or
MAP, but had no pathogenic APC or MUTYH variant. No multiple adenoma case had an outlying number of CRC SNP risk
alleles, but multiple adenoma patients did have a significantly higher number of risk alleles than population controls
(P¼5.7107). The association was stronger in those with Z10 adenomas. The CRC SNPs accounted for 4.3% of the
variation in multiple adenoma risk, with three SNPs (rs6983267, rs10795668, rs3802842) explaining 3.0% of the variation.
In FAP patients, the CRC risk score did not differ significantly from the controls, as we expected given the overwhelming effect
of pathogenic germline APC variants on the phenotype of these cases. More unexpectedly, we found no evidence that the CRC
SNPs act as modifier genes for the number of colorectal adenomas in FAP patients. In conclusion, common colorectal tumour
risk alleles contribute to the development of multiple adenomas in patients without pathogenic germline APC or MUTYH
variants. This phenotype may have ‘polygenic’ or monogenic origins. The risk of CRC in relatives of multiple adenoma cases is
probably much lower for cases with polygenic disease, and this should be taken into account when counselling such patients.
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INTRODUCTION
Most colorectal cancers (CRCs) probably arise from adenomatous
polyps. There is a clinically important subset of patients who are
found to have multiple (five or more) colorectal adenomas, a
phenotype that is suggestive of an inherited genetic predisposition.
Identifying the genetic basis of these patients’ tumours is clinically
informative in terms of determining the natural history of their
disease, the cancer risks in relatives and the optimal means of
surveillance and early treatment.
Some patients with Z5 adenomas have one of the rare Mendelian
polyposis syndromes, such as classical or attenuated familial adeno-
matous polyposis (FAP),1 MUTYH-associated polyposis (MAP)2 or
polymerase proofreading-associated polyposis (PPAP).3 The number
of adenomas is highly variable in each syndrome, and for FAP, the
underlying causes of this phenotypic variation have been studied in
some detail. FAP is caused by germline APC variants and the position
of the variant explains some of the variation in polyp numbers.
For example, although FAP patients usually develop hundreds or
thousands of adenomas, a few individuals with variants in proximal,
distal or alternatively spliced regions of the gene have so-called
attenuated disease, with tens or fewer tumours.4 The position of the
germline APC variants also influences the ‘classical’ (4100
adenomas) FAP phenotype: for example, severe colonic polyposis is
associated with germline variants near codon 1309.5 However, several
studies have also addressed the possibility that modifier genes
unlinked to APC influence the FAP phenotype.6–8
Only a minority of individuals with 5–20 colorectal adenomas
test positive for any pathogenic germline variant9 and the set of
patients with multiple colorectal adenomas is genetically
heterogeneous. Recently, genome-wide association studies (GWAS)
have identified haplotype-tagging single-nucleotide polymorphisms
(SNPs) that are associated with CRC risk in the general
population.10 Some of these variants are close to loci (eg,
GREM1, BMP2, BMP4, POLD3 and MYC) that are functionally
related to the genes involved in the Mendelian polyposis
syndromes. Each SNP has a modest effect size (typically 10–20%
increased risk per allele). By testing individuals with small numbers
of colorectal adenomas (median¼ 1, interquartile range¼ 1–2),
but no history of CRC, we previously showed that some SNPs
predispose to CRC through the development of adenomas.11
In this study, we have examined whether the multiple adenoma
phenotype can be explained in some cases by common risk alleles of
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individually modest effects. We have also assessed whether the
common CRC predisposition SNPs influence the severity of colonic
polyposis in FAP.
MATERIALS AND METHODS
Genomic DNA was extracted from peripheral blood of 178 unrelated
individuals with multiple (5–100) adenomatous polyps (median¼ 10,
IQR¼ 7–17) at first colonoscopy based on routine histopathological reports
(Supplementary Figure 1). Seventy-one patients had CRC at presentation or
subsequently (Table 1), or had a family history of CRC. No case had any polyp
of hamartomatous morphology. A number had several serrated polyps, but in
all cases, the classical adenoma was the majority morphology. Patients were
from throughout the United Kingdom and all were of northern European
ancestry. Patients were not selected on the basis of age, adenoma size or
specific histology. Median age of presentation was 55 years (IQR¼ 48–64) and
34% of patients were female. Adenoma number was not associated with
increased patient age (P¼ 0.97) or with gender (P¼ 0.32). FAP, MAP and
PPAP had been excluded in each case using direct sequencing of (i) the regions
of APC associated with attenuated disease (and the entire gene for those with
close to 100 adenomas), (ii) the common northern EuropeanMUTYH variants
p.Tyr179Cys and p.Gly396Asp12 and (iii) the exonuclease domains of POLE
and POLD1.3 One hundred and forty-two patients (79 families) with FAP and
pathogenic germline APC variants were also studied, as were 30 cases with a
classical FAP phenotype and no identified disease-causing variant in APC,
MUYTH, POLE or POLD1. Data on age, sex and number of polyps at
colectomy from the FAP patients were obtained from the St Mark’s Hospital
Polyposis Registry, Harrow, UK.
For the multiple adenoma and FAP patients, we used KASPar assays
(KBiosciences, Hertfordshire, UK) to genotype 18 published CRC SNPs
(rs6691170 chr1.hg19:g.220112069G4T, rs6687758 chr1.hg19:g.220231571A4G,
rs10936599 chr3.hg19:g.170974795 C4T, rs16892766 chr8.hg19:g.117699864
A4C, rs6983267 chr8.hg19:g.128482487 G4T, rs10795668 chr10.hg19:g.8741225
G4A, rs3802842 chr11.hg19:g.110676919 A4C, rs7136702 chr12.hg19:g.
49166483 C4T, rs11169552 chr12.hg19:g.49441930 C4T, rs4444235 chr14.
hg19:g.53480669 T4C, rs1957636 chr14.hg19:g.53629768 G4A, rs4779584
chr15.hg19:g.30782048 C4T, rs9929218 chr16.hg19:g.67378447 G4A,
rs4939827 chr18.hg19:g.44707461 T4C, rs10411210 chr19.hg19:g.38224140
C4T, rs961253 chr20.hg19:g.6352281 C4A, rs4813802 chr20.hg19:g.6647595
T4G and rs4925386 chr20.hg19:g.60354439 C4T). All of these assays had
previously been validated as showing498% genotype concordance with Illumina
SNP array genotypes as part of the CRC GWAS. Eight samples were excluded for
having individual SNP genotype call rates of o94%. The overall genotyping call
rate was499.5%. None of the markers showed significant deviation from Hardy–
Weinberg equilibrium (P40.05).
As controls, to avoid overlap with the published CRC GWAS, we extracted
SNP genotypes for the 18 SNPs from cancer-free individuals within the
publicly available Colorectal Cancer Family Registry (CFR) (http://coloncfr.org/)
and CGEMS (http://dceg.cancer.gov/research/how-we-study/genomic-studies/
cgems-summary) data sets that had been genotyped using Illumina
genome-wide tagSNP arrays. To control for population stratification, we
conducted principal component analysis to ensure that the CFR samples used
clustered with UK population individuals of northern European ancestry
(Supplementary Figure 2).
We calculated for each individual a SNP risk score defined by
X18
i¼1
bn
where b is the ln(odds ratio (OR)) (40) for each SNP derived from
unconditional logistic regression analysis in CFR cases and CGEMS controls
(Supplementary Tables 1 and 2 and Figure 1), and n is the number of risk
alleles (0–2) carried by that individual. This resulted in a theoretical range of
risk scores between 0 and 4.78, where the minimum and maximum score
would represent individuals homozygous for all the protective and risk alleles
respectively.
RESULTS AND DISCUSSION
The SNP risk score was approximately normally distributed in both
adenoma cases and controls (Shapiro–Wilk test, P40.13). We initially
wondered whether any of the cases had an outlying number of CRC
SNP risk alleles. The maximum number of risk alleles carried by any
patient was 26/36, equivalent to a risk score of 3.53. Four cases and
three controls had risk scores of over 3.40. These data suggested that
the risk score had limited use as a predictor of multiple adenomas on
an individual basis. This result was not unexpected, given that the
known CRC SNPs account for only a minority of adenoma risk.11
As a more general test of the hypothesis that common risk alleles
contribute to the multiple adenoma phenotype, we compared the
SNP risk score distributions in multiple adenoma cases and controls.
There was a significantly higher risk score (P¼ 5.8 107, t-test;
Table 1 and Figure 1) in multiple adenoma cases (mean¼ 2.44,
SD¼ 0.40) than controls (mean¼ 2.27, SD¼ 0.42). The association
remained present (P¼ 0.0011) when the analysis was restricted to the
107 cases with no known personal or family history of CRC (mean
score¼ 2.41, SD¼ 0.40). Of the 178 multiple adenoma cases, 103 had
Z10 adenomas and 75 had 5–9 adenomas. Both case groups
individually had significantly higher risk scores than controls
(Table 1 and Figure 1), but in the group with Z10 adenomas, the
mean risk score was higher (2.48) than that in the patients with 5–9
adenomas (2.39). Ordered logistic regression analysis on the three
groups (10þ adenomas vs 5–9 adenomas vs population controls)
showed that the risk score was correlated with adenoma numbers
(P¼ 9.5 107).
The 18 CRC SNPs explained 4.3% of the variance in the risk of
multiple adenomas. Using multivariate logistic regression to assess
specific polymorphisms, we found that three individual SNPs,
rs6983267 (OR¼ 1.54, 95% CI: 1.21–1.97, P¼ 3.74 104),
rs10795668 (OR¼ 0.64, 95% CI: 0.49–0.84, P¼ 0.00148) and
rs3802842 (OR¼ 1.31, 95% CI: 1.03–1.69, P¼ 0.0278) were nomin-
ally significantly associated with the multiple adenoma phenotype.
These three SNPs alone explained B3% of the variance in multiple
adenoma risk.
Of note, Hes et al13 recently reported associations between
individual CRC SNPs and adenoma risk in a similar data set to
ours, although no risk score was calculated. Hes et al13 found
rs3802842 to be the SNP most significantly associated with
adenoma risk, with additional evidence for associations with
rs6983267 and with a further SNP, rs4779584. In our previous
analysis of patients with smaller numbers of adenomas, rs3802842
and rs6983267 again showed strong associations with risk, although
Table 1 Summary risk score statistics for each group
n
Mean risk
score
Standard
deviation t P-value
MA 178 2.44 0.40 5.12 5.78107
MA no history CRC 107 2.41 0.40 3.28 0.0011
MA (Z10) 103 2.48 0.39 4.44 1.98105
MA (5–9) 75 2.39 0.40 2.08 0.041
FAP-like, APC wild type 30 2.21 0.41 0.83 0.42
FAP, APC mutant 142 2.25 0.42 0.63 0.53
CFR controls 818 2.27 0.42 — —
MA¼ all multiple adenoma cases; MA no history CRC¼MA cases with no personal or family
history of CRC; MA (Z10)¼MA cases with 10 or more adenomas; MA (5–9)¼M cases with
5–9 adenomas.
t-Test results are shown compared with the control group. All sample sets had normally
distributed risk scores (P40.05, Shapiro–Wilk test).
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rs4779584 did not. For rs10795668, the evidence for an association
with rs10795668 was only moderate in the Hes et al data13 and our
own previous study,11 but the direction and magnitude of effect were
consistent in all three studies. Our other four previously reported
adenoma SNPs (rs10936599, rs4444235, rs1957636, rs4939827,
rs961253)11 were not as well supported by this study or by Hes
et al13 (details not shown), although this might have resulted from the
relatively small sizes and low power of the two multiple adenoma case
collections.
Our set of 142 FAP patients with germline APC variants had a very
similar risk score distribution to the controls, as did the 30 cases with
classical FAP and no identified pathogenic variant in the polyposis
genes (P¼ 0.53 and 0.42 respectively; Table 1). Given the over-
whelming effect of the germline APC variant on the FAP phenotype,
the former result was not unexpected, and provided reassurance that
the controls used were representative of the general UK population.
The severity of colorectal polyposis in our FAP cases (number of
colorectal adenomas at prophylactic colectomy) was known for 64
patients from 30 families with pathogenic germline APC variants.
Including sex, age and the position of the germline APC variant
(codons 1265–1389 vs regions associated with attenuated FAP vs
other)14 as covariates in a linear regression analysis, we tested whether
the CRC SNPs were associated with FAP severity. Although APC
variant position was strongly associated with polyp number (details
not shown), there was no association with any other variable. In
particular, SNP risk score showed very little evidence of a positive
association with polyp number (OR¼ 0.94, 95% CI: 0.87–1.01,
P¼ 0.09), and no individual SNP was nominally associated with
polyp count.
In general, the phenotypic overlap between Mendelian and
‘sporadic’ disease is particularly important for the common cancers,
in terms of the clinical management of cancer families and/or those
with multiple tumours. Our results probably underestimate the effects
of the CRC SNPs on the multiple adenoma phenotype, because the
publicly available population controls were not known to be
adenoma-free; furthermore, there almost certainly exist undiscovered,
common CRC risk variants. A further consideration is that a small
number of our multiple adenomas cases may have carried germline
variants in the mismatch repair genes (MSH2, MLH1, MSH6, PMS2)
or the juvenile polyposis genes (SMAD4, BMPR1A). We were a little
surprised to find no evidence that the CRC SNPs affected the severity
of the colorectal phenotype in FAP cases, because adenoma patho-
genesis is often thought to be similar in FAP and sporadic lesions.
Genotyping of modifier genes could influence the management of
FAP patients – for example, in choosing between ileorectal anasto-
mosis and pouch formation. However, our data suggest that the
known CRC SNPs cannot be used for this purpose.
In conclusion, although unidentified Mendelian predisposition
genes for multiple adenomas may exist, we have shown that common
CRC risk variants are likely to contribute to the multiple adenoma
phenotype. It is highly plausible that some of the multiple adenoma
cases carry additional, unknown susceptibility variants with moderate
or small effects. Multiple adenoma cases in whom the known
Mendelian syndromes have been excluded are often not clinically
distinguishable from the Mendelian conditions of attenuated FAP,
MAP or PPAP. However, some of the multiple adenoma patients will
have ‘polygenic’ rather than monogenic disease, with an accompany-
ing lower risk of CRC in family members. Although polygenic
multiple adenoma cases cannot currently be identified positively by
genetic testing, the existence of non-Mendelian genetic adenoma
aetiology should be recognised when counselling the families of
multiple adenoma patients and monitoring the screening regimens of
at-risk relatives.
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